CellMax Life’s blood-based cancer detecting test can detect adenomas with close to 90 percent accuracy and cancer at 95 percent accuracy.
Eric Berthiaume, MD, was named Providence, R.I.-based University Gastroenterology’s president.
Exelixis’ cabozantinib was approved for use in patients with liver cancer. The drug was already approved for thyroid and renal cancer patients.
More articles on gastronerology:
FDA expands Cabozantinib approval to include liver cancer — 4 insights
5 experts weigh in on new GI-focused practice management companies & their implications
Blood-based CRC test detects adenomas with 90% accuracy — 4 insights
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
